Biotech | February 22, 2022
Prestige BioPharma’s facility receives EU-GMP certification
The facility will manufacture its Herceptin biosimilar, Tuznue
The facility will manufacture its Herceptin biosimilar, Tuznue
AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector
US $ 555,000 invested by Wavemaker Partners in pre-seed round
The investment in Indian clinical technology expertise in Hyderabad comes amid the clinical trials sector's move towards decentralised trials
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
The transaction as well as the open offer is expected to be completed by June this year.
The sale is expected to close in the first quarter of 2022
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
The companies plan to use the proceeds to retire debt and expand operations
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
Subscribe To Our Newsletter & Stay Updated
